Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib With or Without Radiation Therapy for Brain Metastases
NCT02015117Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2014
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trametinib in brain metastases (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Frequency of dose-limiting toxicities at 8 weeks and Quantification of trametinib in resected brain metastatic lesions at 28 days. Started Apr 2014; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02015117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015117.